Brain Metastases Clinical Trials

41 studies are recruiting for brain metastases in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. NTS-WBRT in Brain Metastases

   This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05013892 on ClinicalTrials.gov

2. Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

   This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05064280 on ClinicalTrials.gov

3. EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

   To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy. To learn if using SRS to treat all brain metastases that do not re…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06649058 on ClinicalTrials.gov

4. Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

   This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   3 in total

   Run by

   Joshua Palmer

   See if you can join NCT05987644 on ClinicalTrials.gov

5. Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

   Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg…

   Stage

   Phase 1

   Ages

   19 to 90

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   3 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT03449238 on ClinicalTrials.gov

6. Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

   The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation thera…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05559853 on ClinicalTrials.gov

7. Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

   This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of California Davis Comprehensive Cancer Center, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT05452005 on ClinicalTrials.gov

8. Evaluation of the CONVIVO System

   The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventio…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

   Run by

   Dartmouth-Hitchcock Medical Center

   See if you can join NCT05139277 on ClinicalTrials.gov

9. Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

   To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05700721 on ClinicalTrials.gov

10. Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

    The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combination with mutant BRAF inhibitors or after BRAF/MEK inhibito…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Iowa, Iowa City, Iowa

    Locations

    2 in total

    Run by

    University of Utah

    See if you can join NCT06194929 on ClinicalTrials.gov

11. 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

    Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT07175077 on ClinicalTrials.gov

12. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

    This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Miami Cancer Institute at Baptist Health South Florida, Miami, Florida

    Run by

    Baptist Health South Florida

    See if you can join NCT05554302 on ClinicalTrials.gov

13. Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

    The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    New York-Presbyterian/Weill Cornell Medical Center, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06072807 on ClinicalTrials.gov

14. Stereotactic Magnetic Resonance Guided Radiation Therapy

    This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04115254 on ClinicalTrials.gov

15. Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

    The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main questions it aims to answer are: 1. What are the dynamics of 18F-Flu…

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona

    Run by

    University of Arizona

    See if you can join NCT06055790 on ClinicalTrials.gov

16. Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

    This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05996432 on ClinicalTrials.gov